Codexis, Inc. (NASDAQ:CDXS)
| CAPS Rating |
|
|---|
CDXS
VS S&P 500 (SPY)
CDXS News and Commentary
- Beware Facebook, Hubris Killed Sustainable Chemicals – Blogs @ The Motley Fool
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape – NASDAQ
- What Does Iogen's Fate Mean for Codexis? – Blogs @ The Motley Fool
- Pre-Market Most Active for Apr 25, 2012 : S, BAC, AAPL, QQQ, GLW, SIRI, TS, GSK, BIDU, RDS/A, ARMH, – NASDAQ
- Codexis Says FDA Approved Its Sitagliptin Manufacturing Process – SmartMoney
- Verenium Soars on Asset Sales (VRNM, CDXS, SZYM) – 247wallst
- Will Codexis Cash-In on Cellulases? – Blogs @ The Motley Fool
- Five Ways Solazyme Beat 2011 – Blogs @ The Motley Fool
- Energy Common Sense: Codexis Plays the Shell Game With Management – Blogs @ The Motley Fool
How do you think CDXS will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
45
Outperform
2
Underperform
All-Star Players
12
Outperform
1
Underperform
Wall Street
0
Outperform
0
Underperform
RSS Headlines
Fool UK
